We are live on ! Find out more
AGP

Artia Global Partners Portfolio holdings

AUM $499M
1-Year Est. Return 186.05%
This Fund
S&P 500
This Quarter Est. Return
+21.17%
1 Year Est. Return
+186.05%
3 Year Est. Return
+672.09%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$262M
AUM Growth
–
Cap. Flow
+$248M
Cap. Flow %
94.61%
Top 10 Hldgs %
85.09%
Holding
25
New
25
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
NVO
Novo Nordisk
NVO
+$43.5M
2
LLY icon
Eli Lilly
LLY
+$37M
3
ARGX icon
argenx
ARGX
+$31.9M
4
MRK icon
Merck
MRK
+$27M
5
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$21.3M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 99.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NVO
1
Novo Nordisk
NVO
$216B
$50.2M 19.14%
+742,110
New +$43.5M
LLY icon
2
Eli Lilly
LLY
$1.07T
$38.2M 14.55%
+104,328
New +$37M
ARGX icon
3
argenx
ARGX
$57.4B
$32.3M 12.3%
+85,204
New +$31.9M
MRK icon
4
Merck
MRK
$324B
$29.3M 11.17%
+264,200
New +$27M
KRTX
5
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$19.5M 7.43%
+99,267
New +$21.3M
ABBV icon
6
AbbVie
ABBV
$458B
$14.7M 5.59%
+90,821
New +$13.9M
MRNA icon
7
Moderna
MRNA
$21.5B
$13.4M 5.11%
+74,719
New +$12.2M
ISEE
8
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$10.8M 4.12%
+504,615
New +$10.8M
BIIB icon
9
Biogen
BIIB
$29.9B
$8.31M 3.17%
+30,000
New +$8.47M
SGEN
10
DELISTED
Seagen Inc. Common Stock
SGEN
$6.58M 2.51%
+51,175
New +$6.6M
BNTX icon
11
BioNTech
BNTX
$22.6B
$5.57M 2.12%
+37,108
New +$5.71M
NBIX icon
12
Neurocrine Biosciences
NBIX
$17.7B
$5.37M 2.05%
+45,000
New +$5.27M
AZN icon
13
AstraZeneca
AZN
$263B
$5.27M 2.01%
+38,880
New +$4.88M
ALNY icon
14
Alnylam Pharmaceuticals
ALNY
$36.3B
$3.8M 1.45%
+15,971
New +$3.41M
BMRN icon
15
BioMarin Pharmaceuticals
BMRN
$11.5B
$2.92M 1.11%
+28,217
New +$2.65M
TMO icon
16
Thermo Fisher Scientific
TMO
$211B
$2.8M 1.07%
+5,088
New +$2.7M
RXDX
17
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$2.46M 0.94%
+22,321
New +$1.45M
ITCI
18
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$2.2M 0.84%
+41,600
New +$2.08M
VRTX icon
19
Vertex Pharmaceuticals
VRTX
$121B
$2.05M 0.78%
+7,114
New +$2.17M
MRNA icon
20
CALL
Moderna
MRNA
$21.5B
$1.8M 0.68%
+10,000
New +$1.64M
VKTX icon
21
Viking Therapeutics
VKTX
$4.04B
$1.23M 0.47%
+130,913
New +$584K
VRNA
22
DELISTED
Verona Pharma
VRNA
$1.04M 0.4%
+39,951
New +$532K
WAT icon
23
Waters Corp
WAT
$36.8B
$975K 0.37%
+2,845
New +$900K
AMLX icon
24
Amylyx Pharmaceuticals
AMLX
$2.05B
$882K 0.34%
+23,883
New +$848K
KYMR icon
25
Kymera Therapeutics
KYMR
$9.1B
$749K 0.29%
+30,000
New +$800K

Similar funds

MIP
Marietta Investment Partners Milwaukee, Wisconsin $499M AUM 41.06% 1-Year Est. Return
H2CM
H/2 Credit Manager Stamford, Connecticut $500M AUM 24.68% 1-Year Est. Return
HCI
Harraden Circle Investments New York $499M AUM 24.03% 1-Year Est. Return
KCL
KR Capital LP New York City, New York $499M AUM
PPC
Park Place Capital Homewood, Alabama $499M AUM 14.38% 1-Year Est. Return
HIC
Holderness Investments Company Greensboro, North Carolina $498M AUM 34.39% 1-Year Est. Return
CWM
Centric Wealth Management Chicago, Illinois $501M AUM 15.27% 1-Year Est. Return
HSG
Helen Stephens Group Fort Worth, Texas $501M AUM 16.23% 1-Year Est. Return

Artia Global Partners's Q4 2022 Portfolio in Review

Q4 2022 is the first quarter with a 13F filing on record for Artia Global Partners, which disclosed 25 positions worth $262M. Its ten largest holdings account for 85% of the portfolio.

Its largest position is Novo Nordisk: 742,110 shares worth $50.2M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets.

  • Artia Global Partners's largest Q4 2022 buy was Novo Nordisk: 742,110 shares worth $50.2M.
  • Artia Global Partners's ten largest holdings make up 85% of its $262M portfolio in Q4 2022.
  • Artia Global Partners disclosed 25 positions in Q4 2022, its first 13F filing on record.

Based on Artia Global Partners's 13F filing for Q4 2022, filed 14 Feb 2023.